Overview
Hafnia alvei is a facultatively anaerobic, Gram-negative bacterium belonging to the family Hafniaceae within the order Enterobacterales. It is a commensal member of the human gut microbiome whose abundance appears to inversely correlate with obesity. H. alvei has attracted significant research attention due to its production of ClpB (caseinolytic peptidase B), a protein that acts as a structural homolog of alpha-melanocyte-stimulating hormone (alpha-MSH), a key satiety peptide in the human body. This molecular mimicry mechanism represents a novel approach to appetite regulation and weight management.
Classification
H. alvei belongs to the Enterobacterales order, which includes a diverse group of Gram-negative bacteria found throughout the gastrointestinal tract. While some members of this order include opportunistic pathogens, H. alvei is primarily recognized as a commensal organism in healthy individuals. The species was first described in the mid-20th century and has since been identified in various environmental and clinical contexts. The probiotic strain HA4597 has been specifically selected for its ClpB production and safety profile.
Key Characteristics
The defining feature of H. alvei in the context of gut health is its production of the ClpB protein, which structurally mimics the host satiety hormone alpha-MSH. This molecular mimicry may allow the bacterium to influence appetite signaling pathways, potentially reducing food intake and promoting feelings of fullness. The HA4597 strain has been dosed at 5 x 10^7 CFU per day in clinical trials and has demonstrated effects on appetite regulation, body weight, and fat mass in both preclinical and clinical settings. The enterobacterial ClpB gene richness in the gut microbiome has been found to be lower in obese compared to non-obese individuals.
Health Significance
Research suggests that H. alvei HA4597 may offer clinically meaningful benefits for weight management. Preclinical studies in hyperphagic and diet-induced obese mice demonstrated reduced food intake, body weight, and fat mass with ClpB identified as the primary active molecule. A 12-week human clinical trial in overweight adults showed significantly improved weight loss and satiety compared to placebo. Ongoing research is also exploring its potential role in post-bariatric surgery microbiome restoration and glycemic control. It is important to note that H. alvei may have opportunistic pathogen potential in immunocompromised individuals, so its use should be considered in the context of overall health status. Additional large-scale clinical trials are needed to fully establish its safety and efficacy profile as a probiotic.